Polivy
ASH abstract drop backs Roche’s Polivy in first-line lymphoma
Phil Taylor
antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche
0 Comment
Armed with phase 3 data, Roche preps filing for Polivy in first-line DLBCL
Phil Taylor
antibody-drug conjugate, DLBCL, Haematology, non-Hodgkin lymphoma, Oncology, Polivy, Roche
0 Comment
After a nay from NICE, Scotland says aye to J&J’s Spravato
Phil Taylor
Cablivi, Janssen, NICE, Perjeta, Polivy, Roche, Sanofi, Scottish Medicines Consortium, Spravato
0 Comment
NICE recommends regular NHS funding for Roche’s lymphoma drug Polivy
Richard Staines
cancer, market access, NICE, non-Hodgkin lymphoma, Polivy, Roche
0 Comment
Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals
Phil Taylor
Jazz Pharmaceuticals, Mayzent, Novartis, Polivy, Rigel Pharmaceuticals, Roche
0 Comment